Brief: Wave Life Sciences Announces First-Ever Therapeutic RNA Editing In Humans Achieved In Restoraation-2 Trial Of WVE-006 In Alpha-1 Antitrypsin Deficiency
16/10/2024 13:31
Oct 16 (Reuters) - WAVE Life Sciences Ltd WVE.O :
* WAVE LIFE SCIENCES ANNOUNCES FIRST-EVER THERAPEUTIC RNA
EDITING
IN HUMANS ACHIEVED IN RESTORAATION-2 TRIAL OF WVE-006 IN ALPHA-1
ANTITRYPSIN DEFICIENCY
* WAVE LIFE SCIENCES LTD: EXPECTS TO SHARE MULTIDOSE DATA
FROM
RESTORAATION-2 TRIAL IN 2025
Source text for Eikon: ID:nGNXbTwVpB
Further company coverage: WVE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Wave Life Sciences
See all newsWave Life Sciences Ltd Reports Results For The Quarter Ended June 30: Earnings Summary
Wave Life Sciences Ltd Expected To Post A Loss Of 31 Cents A Share: Earnings Preview
Wave Life Sciences Q1 revenue jumps, beats analyst estimates
Brief: Wave Life Sciences Announces Hearing On Proposed Redomiciliation To The United States
Brief: Wave Life Sciences Announces Proposed Redomiciliation To The United States